The Epidemiology of Lung Metastases

Introduction: Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population of patients with de novo (synchronous) lung metastases using the Surveillance, Epidemiology and End Results (SEER) database. Materials and Me...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in medicine Vol. 8; p. 723396
Main Authors Chen, Hanbo, Stoltzfus, Kelsey C., Lehrer, Eric J., Horn, Samantha R., Siva, Shankar, Trifiletti, Daniel M., Meng, Mao-Bin, Verma, Vivek, Louie, Alexander V., Zaorsky, Nicholas G.
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 20.09.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Introduction: Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population of patients with de novo (synchronous) lung metastases using the Surveillance, Epidemiology and End Results (SEER) database. Materials and Methods: Baseline characteristics of lung metastasis patients were obtained from SEER case listings. Incidence rates and counts of synchronous lung metastasis were also obtained using the SEER * Stat software. Survival outcomes were analyzed using univariate and multivariable Cox regressions, controlling for confounders. An alpha threshold of 0.05 was used for statistical significance and p -values were subject to correction for multiple comparisons. Results: The age-adjusted incidence rate of synchronous lung metastasis was 17.92 per 100,000 between 2010 and 2015. Synchronous lung metastases most commonly arose from primary lung cancers, colorectal cancers, kidney cancers, pancreatic cancers and breast cancers. During this time period, 4% of all cancer cases presented with synchronous lung metastasis. The percentage of patients presenting with synchronous lung metastasis ranged from 0.5% of all prostate cancers to 13% of all primary lung cancers. The percentage of all cancer cases presenting with synchronous lung metastasis increased over time. De novo metastatic patients with lung metastases had worse overall survival [hazard ratio = 1.22 (1.21–1.23), p < 0.001] compared to those with only extrapulmonary metastases, controlling for potential confounders. Conclusions: Synchronous lung metastasis occurs frequently and is an independent predictors of poor patient outcomes. As treatment for lung metastases becomes more complicated, patients with synchronous lung metastasis represent a high-risk population.
AbstractList Introduction: Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population of patients with de novo (synchronous) lung metastases using the Surveillance, Epidemiology and End Results (SEER) database. Materials and Methods: Baseline characteristics of lung metastasis patients were obtained from SEER case listings. Incidence rates and counts of synchronous lung metastasis were also obtained using the SEER * Stat software. Survival outcomes were analyzed using univariate and multivariable Cox regressions, controlling for confounders. An alpha threshold of 0.05 was used for statistical significance and p -values were subject to correction for multiple comparisons. Results: The age-adjusted incidence rate of synchronous lung metastasis was 17.92 per 100,000 between 2010 and 2015. Synchronous lung metastases most commonly arose from primary lung cancers, colorectal cancers, kidney cancers, pancreatic cancers and breast cancers. During this time period, 4% of all cancer cases presented with synchronous lung metastasis. The percentage of patients presenting with synchronous lung metastasis ranged from 0.5% of all prostate cancers to 13% of all primary lung cancers. The percentage of all cancer cases presenting with synchronous lung metastasis increased over time. De novo metastatic patients with lung metastases had worse overall survival [hazard ratio = 1.22 (1.21–1.23), p < 0.001] compared to those with only extrapulmonary metastases, controlling for potential confounders. Conclusions: Synchronous lung metastasis occurs frequently and is an independent predictors of poor patient outcomes. As treatment for lung metastases becomes more complicated, patients with synchronous lung metastasis represent a high-risk population.
Introduction: Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population of patients with de novo (synchronous) lung metastases using the Surveillance, Epidemiology and End Results (SEER) database.Materials and Methods: Baseline characteristics of lung metastasis patients were obtained from SEER case listings. Incidence rates and counts of synchronous lung metastasis were also obtained using the SEER*Stat software. Survival outcomes were analyzed using univariate and multivariable Cox regressions, controlling for confounders. An alpha threshold of 0.05 was used for statistical significance and p-values were subject to correction for multiple comparisons.Results: The age-adjusted incidence rate of synchronous lung metastasis was 17.92 per 100,000 between 2010 and 2015. Synchronous lung metastases most commonly arose from primary lung cancers, colorectal cancers, kidney cancers, pancreatic cancers and breast cancers. During this time period, 4% of all cancer cases presented with synchronous lung metastasis. The percentage of patients presenting with synchronous lung metastasis ranged from 0.5% of all prostate cancers to 13% of all primary lung cancers. The percentage of all cancer cases presenting with synchronous lung metastasis increased over time. De novo metastatic patients with lung metastases had worse overall survival [hazard ratio = 1.22 (1.21–1.23), p < 0.001] compared to those with only extrapulmonary metastases, controlling for potential confounders.Conclusions: Synchronous lung metastasis occurs frequently and is an independent predictors of poor patient outcomes. As treatment for lung metastases becomes more complicated, patients with synchronous lung metastasis represent a high-risk population.
Introduction: Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population of patients with de novo (synchronous) lung metastases using the Surveillance, Epidemiology and End Results (SEER) database. Materials and Methods: Baseline characteristics of lung metastasis patients were obtained from SEER case listings. Incidence rates and counts of synchronous lung metastasis were also obtained using the SEER*Stat software. Survival outcomes were analyzed using univariate and multivariable Cox regressions, controlling for confounders. An alpha threshold of 0.05 was used for statistical significance and p-values were subject to correction for multiple comparisons. Results: The age-adjusted incidence rate of synchronous lung metastasis was 17.92 per 100,000 between 2010 and 2015. Synchronous lung metastases most commonly arose from primary lung cancers, colorectal cancers, kidney cancers, pancreatic cancers and breast cancers. During this time period, 4% of all cancer cases presented with synchronous lung metastasis. The percentage of patients presenting with synchronous lung metastasis ranged from 0.5% of all prostate cancers to 13% of all primary lung cancers. The percentage of all cancer cases presenting with synchronous lung metastasis increased over time. De novo metastatic patients with lung metastases had worse overall survival [hazard ratio = 1.22 (1.21-1.23), p < 0.001] compared to those with only extrapulmonary metastases, controlling for potential confounders. Conclusions: Synchronous lung metastasis occurs frequently and is an independent predictors of poor patient outcomes. As treatment for lung metastases becomes more complicated, patients with synchronous lung metastasis represent a high-risk population.Introduction: Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population of patients with de novo (synchronous) lung metastases using the Surveillance, Epidemiology and End Results (SEER) database. Materials and Methods: Baseline characteristics of lung metastasis patients were obtained from SEER case listings. Incidence rates and counts of synchronous lung metastasis were also obtained using the SEER*Stat software. Survival outcomes were analyzed using univariate and multivariable Cox regressions, controlling for confounders. An alpha threshold of 0.05 was used for statistical significance and p-values were subject to correction for multiple comparisons. Results: The age-adjusted incidence rate of synchronous lung metastasis was 17.92 per 100,000 between 2010 and 2015. Synchronous lung metastases most commonly arose from primary lung cancers, colorectal cancers, kidney cancers, pancreatic cancers and breast cancers. During this time period, 4% of all cancer cases presented with synchronous lung metastasis. The percentage of patients presenting with synchronous lung metastasis ranged from 0.5% of all prostate cancers to 13% of all primary lung cancers. The percentage of all cancer cases presenting with synchronous lung metastasis increased over time. De novo metastatic patients with lung metastases had worse overall survival [hazard ratio = 1.22 (1.21-1.23), p < 0.001] compared to those with only extrapulmonary metastases, controlling for potential confounders. Conclusions: Synchronous lung metastasis occurs frequently and is an independent predictors of poor patient outcomes. As treatment for lung metastases becomes more complicated, patients with synchronous lung metastasis represent a high-risk population.
Author Meng, Mao-Bin
Stoltzfus, Kelsey C.
Trifiletti, Daniel M.
Horn, Samantha R.
Verma, Vivek
Chen, Hanbo
Siva, Shankar
Zaorsky, Nicholas G.
Lehrer, Eric J.
Louie, Alexander V.
AuthorAffiliation 9 Department of Radiation Oncology, Sunnybrook Health Sciences Centre , Toronto, ON , Canada
3 Department of Public Health Sciences, Penn State Health Milton S. Hershey Medical Center , Hershey, PA , United States
5 Department of Radiation Oncology, Peter MacCallum Cancer Centre , Melbourne, VIC , Australia
6 Department of Radiation Oncology, Mayo Clinic , Jacksonville, FL , United States
4 Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai , New York, NY , United States
7 Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital , Tianjin , China
8 Department of Radiation Oncology, Allegheny General Hospital , Pittsburgh, PA , United States
1 Department of Radiation Oncology, Amsterdam University Medical Centers , Amsterdam , Netherlands
2 Department of Radiation Oncology, Penn State Cancer Institute , Hershey, PA , United States
AuthorAffiliation_xml – name: 5 Department of Radiation Oncology, Peter MacCallum Cancer Centre , Melbourne, VIC , Australia
– name: 2 Department of Radiation Oncology, Penn State Cancer Institute , Hershey, PA , United States
– name: 1 Department of Radiation Oncology, Amsterdam University Medical Centers , Amsterdam , Netherlands
– name: 6 Department of Radiation Oncology, Mayo Clinic , Jacksonville, FL , United States
– name: 7 Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital , Tianjin , China
– name: 4 Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai , New York, NY , United States
– name: 8 Department of Radiation Oncology, Allegheny General Hospital , Pittsburgh, PA , United States
– name: 9 Department of Radiation Oncology, Sunnybrook Health Sciences Centre , Toronto, ON , Canada
– name: 3 Department of Public Health Sciences, Penn State Health Milton S. Hershey Medical Center , Hershey, PA , United States
Author_xml – sequence: 1
  givenname: Hanbo
  surname: Chen
  fullname: Chen, Hanbo
– sequence: 2
  givenname: Kelsey C.
  surname: Stoltzfus
  fullname: Stoltzfus, Kelsey C.
– sequence: 3
  givenname: Eric J.
  surname: Lehrer
  fullname: Lehrer, Eric J.
– sequence: 4
  givenname: Samantha R.
  surname: Horn
  fullname: Horn, Samantha R.
– sequence: 5
  givenname: Shankar
  surname: Siva
  fullname: Siva, Shankar
– sequence: 6
  givenname: Daniel M.
  surname: Trifiletti
  fullname: Trifiletti, Daniel M.
– sequence: 7
  givenname: Mao-Bin
  surname: Meng
  fullname: Meng, Mao-Bin
– sequence: 8
  givenname: Vivek
  surname: Verma
  fullname: Verma, Vivek
– sequence: 9
  givenname: Alexander V.
  surname: Louie
  fullname: Louie, Alexander V.
– sequence: 10
  givenname: Nicholas G.
  surname: Zaorsky
  fullname: Zaorsky, Nicholas G.
BookMark eNp1kU1rGzEQhkVISBw39xwNvfRidzT6WO2lUEy-wCGXBHITknbWkVmvnNW6kH_f3TiFplAYmEEz76Nh3nN23KaWGLvksBDClN_rLVULBOSLAoUo9RGbIJZ6bpR5Pv6rPmMXOW8AgAtUkotTdiak5rpQcsK-Pr7Q7GoXK9rG1KT12yzVs9W-Xc_uqXd5CMpf2EntmkwXH3nKnq6vHpe389XDzd3y52oeFKh-rkxFiOADoCA0dVlrkmA8Oi0DylIRL6QcprBwQQJWXohCQSDkqvayFlN2d-BWyW3srotb173Z5KJ9f0jd2rquj6EhC9JjkN4pEbQUHkrPteYDWxgdfFkOrB8H1m7vhzsFavvONZ-gnzttfLHr9MsaaQwHPQC-fQC69Lqn3NttzIGaxrWU9tmiMgCoeTH-pQ-joUs5d1TbEHvXxzSSY2M52NEwOxpmR8PswbBBCP8I_-z3X8lvTUiX4g
CitedBy_id crossref_primary_10_1136_bmjopen_2023_072469
crossref_primary_10_1007_s11864_023_01144_6
crossref_primary_10_3390_diagnostics12092254
crossref_primary_10_1111_cas_15951
crossref_primary_10_20517_evcna_2023_77
crossref_primary_10_1210_jendso_bvaf034
crossref_primary_10_3390_cancers16112080
crossref_primary_10_3390_cancers17020206
crossref_primary_10_3389_fcell_2024_1449232
crossref_primary_10_3390_diagnostics13010165
crossref_primary_10_1515_oncologie_2024_0138
crossref_primary_10_1007_s11604_022_01302_0
crossref_primary_10_12998_wjcc_v10_i30_10882
crossref_primary_10_1089_thy_2023_0709
crossref_primary_10_1002_rcr2_70031
crossref_primary_10_3389_fcvm_2022_1009765
crossref_primary_10_1021_acsnano_3c03980
crossref_primary_10_3390_cancers16193365
crossref_primary_10_1007_s00281_022_00964_2
crossref_primary_10_1038_s41392_025_02148_4
crossref_primary_10_1007_s10555_023_10120_3
crossref_primary_10_1007_s41973_024_00263_3
crossref_primary_10_1615_CritRevImmunol_2024051316
crossref_primary_10_1038_s43856_023_00304_x
crossref_primary_10_3389_fonc_2023_1116783
crossref_primary_10_1002_advs_202308237
Cites_doi 10.1016/j.radonc.2011.05.033
10.1001/archsurg.142.1.70
10.1016/S0140-6736(18)32487-5
10.1002/cam4.1697
10.3747/co.25.4103
10.1093/annonc/mdq220
10.1136/gut.2010.211557
10.1002/cncr.21778
10.1002/cncr.31549
10.1093/annonc/mdw235
10.1378/chest.12-2346
10.1007/s10585-015-9719-0
10.1016/j.clcc.2017.12.005
10.1126/science.1150224
10.1016/j.cllc.2014.07.001
10.1080/08998280.2005.11928089
10.1093/annonc/mdv037
10.1016/j.eururo.2012.05.068
10.1186/1471-2407-13-36
10.1177/1010428317705082
10.1016/S0003-4975(00)02522-4
10.1038/srep29765
10.1093/jnci/djq029
10.1016/j.lungcan.2014.07.020
10.18632/oncotarget.10740
10.1097/00000658-199905000-00002
10.1016/S0895-4356(00)00314-0
10.1007/s10585-016-9824-8
10.1038/nature03799
10.1111/j.1365-2605.1987.tb00188.x
10.1016/j.cllc.2014.04.003
ContentType Journal Article
Copyright Copyright © 2021 Chen, Stoltzfus, Lehrer, Horn, Siva, Trifiletti, Meng, Verma, Louie and Zaorsky.
Copyright © 2021 Chen, Stoltzfus, Lehrer, Horn, Siva, Trifiletti, Meng, Verma, Louie and Zaorsky. 2021 Chen, Stoltzfus, Lehrer, Horn, Siva, Trifiletti, Meng, Verma, Louie and Zaorsky
Copyright_xml – notice: Copyright © 2021 Chen, Stoltzfus, Lehrer, Horn, Siva, Trifiletti, Meng, Verma, Louie and Zaorsky.
– notice: Copyright © 2021 Chen, Stoltzfus, Lehrer, Horn, Siva, Trifiletti, Meng, Verma, Louie and Zaorsky. 2021 Chen, Stoltzfus, Lehrer, Horn, Siva, Trifiletti, Meng, Verma, Louie and Zaorsky
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fmed.2021.723396
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2296-858X
ExternalDocumentID oai_doaj_org_article_04b2c4ba53c643b09b166158d386cb99
PMC8488106
10_3389_fmed_2021_723396
GroupedDBID 53G
5VS
9T4
AAFWJ
AAYXX
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
GROUPED_DOAJ
HYE
KQ8
M48
M~E
OK1
PGMZT
RPM
7X8
5PM
ID FETCH-LOGICAL-c505t-58de220bc023e28f9f6e408b2a64c2495e174458d27ac402db33750ce215fb4f3
IEDL.DBID DOA
ISSN 2296-858X
IngestDate Wed Aug 27 01:21:10 EDT 2025
Thu Aug 21 18:16:44 EDT 2025
Fri Jul 11 05:23:29 EDT 2025
Tue Jul 01 03:03:23 EDT 2025
Thu Apr 24 22:56:51 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c505t-58de220bc023e28f9f6e408b2a64c2495e174458d27ac402db33750ce215fb4f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Michel Gonzalez, Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland
Reviewed by: Manigreeva Krishnatreya, Bhubaneswar Borooah Cancer Institute, India; Levent Cansever, Yedikule Teaching Hospital, Turkey
This article was submitted to Pulmonary Medicine, a section of the journal Frontiers in Medicine
OpenAccessLink https://doaj.org/article/04b2c4ba53c643b09b166158d386cb99
PMID 34616754
PQID 2580026179
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_04b2c4ba53c643b09b166158d386cb99
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8488106
proquest_miscellaneous_2580026179
crossref_citationtrail_10_3389_fmed_2021_723396
crossref_primary_10_3389_fmed_2021_723396
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-09-20
PublicationDateYYYYMMDD 2021-09-20
PublicationDate_xml – month: 09
  year: 2021
  text: 2021-09-20
  day: 20
PublicationDecade 2020
PublicationTitle Frontiers in medicine
PublicationYear 2021
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Billingsley (B7) 1999; 229
Wang (B22) 2018; 17
Ording (B20) 2017; 34
B26
B27
B28
Bender (B30) 2001; 54
Riihimaki (B4) 2016; 6
Pagani (B10) 2010; 102
Loukeri (B36) 2015; 16
van der Geest (B21) 2015; 32
Palma (B8) 2019; 393
Negoita (B33) 2018; 124
Mitry (B2) 2010; 59
Ashworth (B23) 2014; 15
Riihimaki (B5) 2016; 7
B34
Gao (B12) 2008; 319
Schroder (B32) 2012; 62
B37
Minn (B11) 2005; 436
Hess (B18) 2006; 106
Vogelzang (B1) 1987; 10
Rehders (B13) 2007; 142
Headrick (B14) 2001; 71
Holm (B29) 1979; 6
Van Cutsem (B9) 2016; 27
Wu SG Li (B19) 2017; 39
Dawood (B25) 2010; 21
Nana-Sinkam (B35) 2013; 143
Takeda (B16) 2011; 101
Nazha (B24) 2018; 25
Riihimaki (B6) 2013; 13
Riihimaki (B17) 2018; 7
Griffeth (B31) 2005; 18
Riihimaki (B3) 2014; 86
de Baere (B15) 2015; 26
References_xml – volume: 101
  start-page: 255
  year: 2011
  ident: B16
  article-title: Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer
  publication-title: Radiother Oncol.
  doi: 10.1016/j.radonc.2011.05.033
– volume: 142
  start-page: 70
  year: 2007
  ident: B13
  article-title: Benefit of surgical treatment of lung metastasis in soft tissue sarcoma
  publication-title: Arch Surg.
  doi: 10.1001/archsurg.142.1.70
– volume: 6
  start-page: 65
  year: 1979
  ident: B29
  article-title: A simple sequentially rejective multiple test procedure
  publication-title: Scand J Statist.
– volume: 393
  start-page: 2051
  year: 2019
  ident: B8
  article-title: Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(18)32487-5
– volume: 7
  start-page: 5534
  year: 2018
  ident: B17
  article-title: Clinical landscape of cancer metastases
  publication-title: Cancer Med.
  doi: 10.1002/cam4.1697
– volume: 25
  start-page: e576
  year: 2018
  ident: B24
  article-title: Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting
  publication-title: Curr Oncol.
  doi: 10.3747/co.25.4103
– ident: B27
– volume: 21
  start-page: 2169
  year: 2010
  ident: B25
  article-title: Survival differences among women with de novo stage IV and relapsed breast cancer
  publication-title: Ann Oncol.
  doi: 10.1093/annonc/mdq220
– volume: 59
  start-page: 1383
  year: 2010
  ident: B2
  article-title: Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study
  publication-title: Gut.
  doi: 10.1136/gut.2010.211557
– volume: 106
  start-page: 1624
  year: 2006
  ident: B18
  article-title: Metastatic patterns in adenocarcinoma
  publication-title: Cancer.
  doi: 10.1002/cncr.21778
– volume: 124
  start-page: 2801
  year: 2018
  ident: B33
  article-title: Annual Report to the Nation on the Status of Cancer, part II: recent changes in prostate cancer trends and disease characteristics
  publication-title: Cancer.
  doi: 10.1002/cncr.31549
– volume: 27
  start-page: 1386
  year: 2016
  ident: B9
  article-title: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
  publication-title: Ann Oncol.
  doi: 10.1093/annonc/mdw235
– volume: 143
  start-page: e30S
  year: 2013
  ident: B35
  article-title: Molecular biology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
  publication-title: Chest
  doi: 10.1378/chest.12-2346
– volume: 32
  start-page: 457
  year: 2015
  ident: B21
  article-title: Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases
  publication-title: Clin Exp Metastasis.
  doi: 10.1007/s10585-015-9719-0
– volume: 17
  start-page: e233
  year: 2018
  ident: B22
  article-title: Survival benefit of palliative local treatments and efficacy of different pharmacotherapies in colorectal cancer with lung metastasis: results from a large retrospective study
  publication-title: Clin Colorectal Cancer.
  doi: 10.1016/j.clcc.2017.12.005
– volume: 319
  start-page: 195
  year: 2008
  ident: B12
  article-title: Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis
  publication-title: Science.
  doi: 10.1126/science.1150224
– volume: 16
  start-page: 15
  year: 2015
  ident: B36
  article-title: Metachronous and synchronous primary lung cancers: diagnostic aspects, surgical treatment, and prognosis
  publication-title: Clin Lung Cancer.
  doi: 10.1016/j.cllc.2014.07.001
– volume: 18
  start-page: 321
  year: 2005
  ident: B31
  article-title: Use of PET/CT scanning in cancer patients: technical and practical considerations
  publication-title: Proc.
  doi: 10.1080/08998280.2005.11928089
– ident: B37
– volume: 26
  start-page: 987
  year: 2015
  ident: B15
  article-title: Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases
  publication-title: Ann Oncol.
  doi: 10.1093/annonc/mdv037
– volume: 62
  start-page: 745
  year: 2012
  ident: B32
  article-title: Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)
  publication-title: Eur Urol.
  doi: 10.1016/j.eururo.2012.05.068
– volume: 13
  start-page: 36
  year: 2013
  ident: B6
  article-title: Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer
  publication-title: BMC Cancer.
  doi: 10.1186/1471-2407-13-36
– volume: 39
  start-page: 1010428317705082
  year: 2017
  ident: B19
  article-title: The effect of distant metastases sites on survival in de novo stage-IV breast cancer: a SEER database analysis
  publication-title: Tumour Biol.
  doi: 10.1177/1010428317705082
– volume: 71
  start-page: 975
  year: 2001
  ident: B14
  article-title: Surgical treatment of hepatic and pulmonary metastases from colon cancer
  publication-title: Ann Thorac Surg.
  doi: 10.1016/S0003-4975(00)02522-4
– volume: 6
  start-page: 29765
  year: 2016
  ident: B4
  article-title: Patterns of metastasis in colon and rectal cancer
  publication-title: Sci Rep.
  doi: 10.1038/srep29765
– ident: B26
– volume: 102
  start-page: 456
  year: 2010
  ident: B10
  article-title: International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?
  publication-title: J Natl Cancer Inst.
  doi: 10.1093/jnci/djq029
– ident: B28
– volume: 86
  start-page: 78
  year: 2014
  ident: B3
  article-title: Metastatic sites and survival in lung cancer
  publication-title: Lung Cancer.
  doi: 10.1016/j.lungcan.2014.07.020
– volume: 7
  start-page: 52307
  year: 2016
  ident: B5
  article-title: Metastatic spread in patients with gastric cancer
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.10740
– volume: 229
  start-page: 602
  year: 1999
  ident: B7
  article-title: Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival
  publication-title: Ann Surg.
  doi: 10.1097/00000658-199905000-00002
– volume: 54
  start-page: 343
  year: 2001
  ident: B30
  article-title: Adjusting for multiple testing–when and how?
  publication-title: J Clin Epidemiol.
  doi: 10.1016/S0895-4356(00)00314-0
– volume: 34
  start-page: 93
  year: 2017
  ident: B20
  article-title: Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study
  publication-title: Clin Exp Metastasis.
  doi: 10.1007/s10585-016-9824-8
– volume: 436
  start-page: 518
  year: 2005
  ident: B11
  article-title: Genes that mediate breast cancer metastasis to lung
  publication-title: Nature.
  doi: 10.1038/nature03799
– volume: 10
  start-page: 225
  year: 1987
  ident: B1
  article-title: Prognostic factors in metastatic testicular cancer
  publication-title: Int J Androl.
  doi: 10.1111/j.1365-2605.1987.tb00188.x
– volume: 15
  start-page: 346
  year: 2014
  ident: B23
  article-title: An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer
  publication-title: Clin Lung Cancer.
  doi: 10.1016/j.cllc.2014.04.003
– ident: B34
SSID ssj0001325413
Score 2.361005
Snippet Introduction: Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population...
Introduction: Lung metastasis is usually associated with poor outcomes in cancer patients. This study was performed to characterize and analyze the population...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 723396
SubjectTerms cancer
epidemiology
lung cancer
Medicine
metastases
oncology
SummonAdditionalLinks – databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8NAEF60gngRn1hfRPTiITXd3bwOIiotRYwnC70tu5uNCiXRJgX7751J0tZA8eQlh2Q3j5lM5vt2N98QciVRZQ0H3WM_BoISutqWNJGwCY30Eyd0NP47HL14gyF_Grmj5e_RtQHzldQO60kNJ-PO99fsDgL-Fhkn5FvwgEHNT9rt-JSx0FsnG5CXfAzTqAb75YgLAzLUZdVc5cqOjdxUSvg3cGdz1eSvNNTfIds1frTuK4fvkjWT7pHNqJ4h3yeX4Hertyz7OrOyxHqGiLYiU0iAgrnJD8iw33t9HNh1IQRbA0ApbDeIDaWO0pBgDQ2SMPEMdwJFpcc1Fo82wCs4tKK-1EAIY8UYIAFtIJ8niifskLTSLDVHxGLdOOFeAEQh5twPZHkOlA8HnMeYx9rkZm4CoWuVcCxWMRbAFtBoAo0m0GiiMlqbXC96fFYKGX-0fUCrLtqhtnW5I5u8iTpUhMMV1VxJl2mAS8oJVRdABDwdCzytwrBNLuY-ERALOMEhU5NNc0HdoJKYhzZ-w1mNKzaPpB_vpap2AJ8y4MfH_3GLJ2QLnxrXlVDnlLSKydScAXgp1Hn5Tv4AzLTrPg
  priority: 102
  providerName: Scholars Portal
Title The Epidemiology of Lung Metastases
URI https://www.proquest.com/docview/2580026179
https://pubmed.ncbi.nlm.nih.gov/PMC8488106
https://doaj.org/article/04b2c4ba53c643b09b166158d386cb99
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07T8MwELYQA2JBPEV5KQgWhtDEdhJnBNSqQoSJSt0s27EFEkoRTQf-PXdxWpIFFpYMiZPYd06--_z4jpBrhSprOOheZiUQlDwxoaJOwSG3KnNRHhncO1w8p5Mpf5wls06qL1wT5uWBveGGEdfUcK0SZgA8dZTrGCAlESUTqdF5s3UPMK9DpprRFQbEJ2Z-XhJYWA5usigMSuPbjDKGGv0dHGrk-nsxZn-FZAdyxrtkp40Vgztfxz2yYat9slW0s-EH5Ap8HIx-Urx-BXMXPMHXGxS2VhD2LezikEzHo5eHSdgmPQgNBCN1CC2zlEbaAJhaKlzuUssjoalKucFE0RY4BIdSNFMGyF-pGQPUNxaw22nu2BHZrOaVPSYBi0vHUwGkoOQ8E6p5BkqFQ0zHWMoGZLgygTStIjgmpniXwAzQaBKNJtFo0httQG7Wd3x4NYxfyt6jVdflUMe6OQHela135V_eHZDLlU8k9HuczFCVnS8XkibCy8lDmaznrN4b-1eqt9dGQVvAbwu48Ml_VPGUbGOrcQ0Jjc7IZv25tOcQqNT6oumTcCy4-Ab20OPb
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Epidemiology+of+Lung+Metastases&rft.jtitle=Frontiers+in+medicine&rft.au=Hanbo+Chen&rft.au=Kelsey+C.+Stoltzfus&rft.au=Kelsey+C.+Stoltzfus&rft.au=Eric+J.+Lehrer&rft.date=2021-09-20&rft.pub=Frontiers+Media+S.A&rft.eissn=2296-858X&rft.volume=8&rft_id=info:doi/10.3389%2Ffmed.2021.723396&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_04b2c4ba53c643b09b166158d386cb99
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-858X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-858X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-858X&client=summon